andrew huberman semaglutide Neuroscientist believes GLP-1s could eradicate obesity and fundamentally reshape public health. >> 👇Link👇 Semaglutide Insights | Ask Huberman

Works well for many patients, especially those new to GLP-1 therapy

Anyone with a health condition that might have made it unsafe or challenging to participate was left out of the semaglutide clinical trials, for example, according to the study protocol, a precaution similar to other clinical trials

Meaningful, visible weight loss typically becomes apparent within the first two to four weeks, with progress continuing throughout the protocol

Individuals who used Ozempic, Wegovy, or Rybelsus and now struggle with gastroparesis, also known as stomach paralysis, might be entitled to financial compensation, as Novo Nordisk failed to warn of this serious, often irreversible adverse effect